Clinical Trial Update: Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of pembrolizumab and olaparib for recurrent/advanced gastric cancer and gastroesophageal junction cancer i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yonsei University | Conditions: Gastric Cancer Stage IV | Phase 1, Phase 2 | Status: RECRUITING